Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4564644 | 0.88 | SLC6A2 (0.66) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3951032 | 0.85 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3960491 | 0.85 | SLC6A2 (0.48) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3956973 | 0.85 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4704627 | 0.85 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3960365 | 0.84 | SLC6A2 (0.42) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3956420 | 0.84 | SLC6A2 (0.54) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL27681902 | 0.83 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3957574 | 0.83 | CHRM3 (0.35) | SLC6A2SLC6A4 | |
| SCHEMBL3987392 | 0.80 | SLC6A2 (0.48) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7524846-B2 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2009-04-28 | — | — | US | disclosed |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | SLC6A2 108/4885SLC6A3 80/4885SLC6A4 31/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | SLC6A2 71/4885SLC6A3 116/4885SLC6A4 44/4885 |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | COMT, MAOA, HTR3A | SLC6A2 63/4885SLC6A3 74/4885SLC6A4 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.